[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342959-105":59,"doc-detail-342959-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","construction-and-validation-of-a-prognostic-signature-based-on-anoikis-related-lncrnas-in-lung-adenocarcinoma","Construction and validation of a prognostic signature based on anoikis-related lncRNAs in lung adenocarcinoma","","Lung adenocarcinoma (LUAD) remains a leading cause of cancer mortality, with survival outcomes that are still poor. Anoikis—an apoptosis program triggered by loss of attachment—contributes to tumor development, yet the roles of anoikis-related lncRNAs (ARLRs) in LUAD are not well defined. TCGA data were analyzed using coexpression and Cox regression to construct an ARLR prognostic signature. The model was validated using K-M and ROC analyses, then translated into a nomogram. Enrichment linked lncRNAs to tumor progression, and low-risk patients showed better survival, higher immune scores, and distinct immune infiltration patterns, along with different anticancer drug sensitivities. One ARLR, AC026355.2, was further validated in LUAD cells.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/construction-and-validation-of-a-prognostic-signature-based-on-anoikis-related-lncrnas-in-lung-adenocarcinoma/342959/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/construction-and-validation-of-a-prognostic-signature-based-on-anoikis-related-lncrnas-in-lung-adenocarcinoma/342959.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What data and statistical methods were used to build the prognostic signature?","Question",{"text":112,"@type":113},"Genomic and clinical information from the TCGA database was queried. A prognostic signature for ARLRs was established using coexpression analysis and Cox regression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the signature validated and evaluated for clinical use?",{"text":117,"@type":113},"Accuracy was assessed with Kaplan–Meier (K-M) curves and receiver operating characteristic (ROC) curves. The signature was then used to develop a nomogram for evaluation.",{"name":119,"@type":110,"acceptedAnswer":120},"What biological and clinical differences were observed between low-risk and high-risk groups?",{"text":121,"@type":113},"Functional enrichment implicated lncRNAs in tumor progression. Low-risk patients showed improved prognosis, increased immune cell infiltration, higher immune scores, and different anticancer drug sensitivities compared with high-risk patients.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342959,1790526585,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","[www.aging-us.com](www.aging-us.com) AGING 2024, Vol. 16, No. 11  \nResearch Paper  \nConstruction and validation of a prognostic signature based on anoikis-related lncRNAs in lung adenocarcinoma  \nXiaoqi Dong 1, Chuan Shao 1, Shuguang Xu 1, Jinjing Tu 1, Wenjing Xu2, Dahua Chen3, Yaodong Tang1  \n1 Department of Pulmonary and Critical Care Medicine, Ningbo Medical Center Lihuili Hospital (Lihuili Hospital Affiliated to Ningbo University), Ningbo, China  \n2 Ningbo University Health Science Center, Ningbo, China  \n3 Department of Gastroenterology, Ningbo Medical Center Lihuili Hospital (Lihuili Hospital Affiliated to Ningbo University), Ningbo, China  \nCorrespondence to: Yaodong Tang; email: [nblhltyd@163.com](nblhltyd@163.com), [https://orcid.org/0009-0009-4268-0503](https://orcid.org/0009-0009-4268-0503)[ ](https://orcid.org/0009-0009-4268-0503)[Keywords:](Keywords: lung adenocarcinoma)[ lung adenocarcinoma](Keywords: lung adenocarcinoma), lncRNAs, anoikis, signature, prognosis  \nReceived: August 11, 2023 Accepted: May 2, 2024 Published: June 7, 2024  \nCopyright: © 2024 Dong et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nABSTRACT  \nLung adenocarcinoma (LUAD) is the most common type of lung cancer and is characterized by a high death rate and a poor prospect for survival. Anoikis, which is a kind of programmed cell apoptosis, is an important factor in the advancement of tumors. Nonetheless, the function of anoikis-related lncRNAs (ARLRs) in LUAD is still not well understood. The TCGA database was queried for genomic and clinical information. A prognostic signature for ARLRs was established via the use of coexpression analysis and Cox regression. Validation of the model’s accuracy was conducted utilizing K-M curves and receiver operating characteristic (ROC) curves, and the signature was utilized to develop a nomogram. LncRNAs were implicated in the progression of tumors, as determined by functional enrichment analysis. There was an improvement in prognosis, increased immune cell infiltration, and higher immune scores among the low-risk patients. Additionally, we found that the two groups had varied anticancer drug sensitivities, which could help guide treatment. The impact of one ARLR, AC026355.2, on migration and invasion was validated by in vitro experiments in LUAD cells. Herein, a new lncRNA signature associated with anoikis was identified and estimated, potentially serving as a prognostic indicator for LUAD patients.  \nINTRODUCTION  \nUndoubtedly, lung cancer is a prevalent malignant tumor that poses a significant risk to the well-being and life of humans, resulting in significant morbidity and mortality [1] . Non-small cell lung cancers (NSCLCs) comprise around 80% of lung cancers, with lung adenocarcinomas (LUADs) representing more than 70% of these cases [2, 3] . Nearly 40% of individuals with non-small cell lung cancer (NSCLC) exhibit distant metastases after they are first diagnosed and this number rises to 40% while undergoing therapy [4] . Nevertheless, therapies for distant metastases have  \nlimited effectiveness, leading to unsatisfactory outcomes. Even small primary tumors are susceptible to metastasis in LUAD [5] . Consequently, the 5-year survival rate for patients afflicted with advanced LUADis below 20%, indicating an unfavorable prognosis [6] . The discovery of prognostic markers for the prediction of LUAD patients’ prognoses and survival rates is a pressing concern.  \nAnoikis, which is generated through cell detachment from the extracellular matrix (ECM), is an exceptional form of programmed cell apoptosis that is critically involved in the development, homeostasis and  \n9899  \nmetastasis of tumors. Cancer cells, as opposed to healthy epithelial cells, are resistant to anoikis and are not dependent on EC","cbCaibyOzLIisClX","https://ap.wps.com/l/cbCaibyOzLIisClX","pdf",4007547,"English","# Abstract\n## Methods\n## Results\n## Functional validation\n# Introduction\n## Clinical burden of LUAD\n## Biological background: anoikis and resistance\n## Biological background: lncRNAs and cancer\n## Research gap and study aim","[{\"question\":\"What data and statistical methods were used to build the prognostic signature?\",\"answer\":\"Genomic and clinical information from the TCGA database was queried. A prognostic signature for ARLRs was established using coexpression analysis and Cox regression.\"},{\"question\":\"How was the signature validated and evaluated for clinical use?\",\"answer\":\"Accuracy was assessed with Kaplan–Meier (K-M) curves and receiver operating characteristic (ROC) curves. The signature was then used to develop a nomogram for evaluation.\"},{\"question\":\"What biological and clinical differences were observed between low-risk and high-risk groups?\",\"answer\":\"Functional enrichment implicated lncRNAs in tumor progression. Low-risk patients showed improved prognosis, increased immune cell infiltration, higher immune scores, and different anticancer drug sensitivities compared with high-risk patients.\"}]","Construction and validation of a prognostic signature based on anoikis-related lncRNAs in lung adenocarcinoma | PDF",1790049097,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/af042835214b74606d454a80c4a75e5a.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/55993a5828ec80bfce8c296b09b058d7.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/278f5f72a846bf12afbc4d54c947abeb.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/991cdfb467d68f67ce241e9265f806e1.webp",980,1268]